Sintx Technologies, Inc. (SINT)
SINTNASDAQ-CMMedical/Dental Instruments
$1.55
+0.0700 (+4.73%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $11.72m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.40 to $4.46
- Average volume
- 52.6k
- Previous close
- $1.48
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $9.50, +512.9% from here
Earnings
next estimate $-0.3500Next report
Mar 2026
-6.1%
Jun 2026
+7.4%
Sep 2026
+22.6%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $208.0k | $290.0k | $380.0k | $452.0k |
| Gross profit | $93.0k | $188.0k | $144.0k | $278.0k |
| Operating income | -$3.35m | -$2.32m | -$3.21m | -$2.89m |
| Net income | -$3.54m | -$2.21m | -$2.82m | -$2.71m |
Last four quarters: revenue $1.33m, margin -848.2%, free cash flow -$10.34m
News
8 latest- SINTX Technologies, Inc. Reports Third Quarter 2026 Revenue of approximately $2.2 millionFintel · 5 days ago
- What Makes SINTX TECHNOLOGIES (SINT) a New Buy StockZacks · Oct 8, 2026
- SINTX TECHNOLOGIES (SINT) Moves to Buy: Rationale Behind the UpgradeZacks · Aug 19, 2026
- AxoGen (AXGN) Tops Q2 Earnings and Revenue EstimatesZacks · Jul 29, 2026
- PAVmed Inc. (PAVM) Reports Q1 Loss, Lags Revenue EstimatesZacks · May 15, 2026
- Artivion (AORT) Q1 Earnings and Revenues Surpass EstimatesZacks · May 7, 2026
- Waters (WAT) Beats Q1 Earnings and Revenue EstimatesZacks · May 5, 2026
- HC Wainwright & Co. Initiates Coverage of Sintx Technologies (SINT) with Buy RecommendationFintel · Apr 13, 2026
The company
Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced biomaterials company that develops, manufactures, and commercializes patented and proprietary silicon nitride ceramic biomaterials, composites, devices, and related ceramics technologies for medical and other specialized industrial applications. SINTX has 20 years of experience innovating silicon nitride technologies and operates under a quality management system certified to ISO 13485:2016 and AS9100D, with a product portfolio that includes insulators for Tier 1 aerospace suppliers, the FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System for reconstructive surgery, OEM manufacturing of FDA-cleared spinal implants, and its SiNERGY technology platform being developed for biocomposite and 3D printing applications.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- sintx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.